Profile data is unavailable for this security.
About the company
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
- Revenue in USD (TTM)15.97m
- Net income in USD-107.69m
- Incorporated2020
- Employees136.00
- LocationLiquidia Corp419 Davis Drive, Suite 100MORRISVILLE 27560United StatesUSA
- Phone+1 (919) 328-4400
- Fax+1 (919) 328-4402
- Websitehttps://www.liquidia.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nurix Therapeutics Inc | 80.89m | -144.73m | 923.95m | 284.00 | -- | 4.59 | -- | 11.55 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 937.72m | 284.00 | -- | -- | -- | 36.64 | -4.45 | -4.45 | 1.08 | -- | 0.0853 | -- | 1.66 | 146,514.10 | -34.46 | -29.45 | -38.51 | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | 0.0796 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
Innoviva Inc | 311.59m | 181.39m | 958.53m | 112.00 | 7.21 | 1.41 | 4.49 | 3.16 | 2.19 | 2.19 | 3.88 | 11.21 | 0.2599 | 0.9935 | 4.10 | 2,782,054.00 | 15.13 | 26.24 | 15.57 | 28.53 | 86.12 | -- | 58.21 | 76.84 | 9.17 | -- | 0.3883 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 963.28m | 267.00 | -- | -- | -- | 2.42 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
ProKidney Corp | 0.00 | -35.30m | 973.13m | 163.00 | -- | -- | -- | -- | -0.567 | -0.567 | 0.00 | -17.79 | 0.00 | -- | -- | 0.00 | -30.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
Liquidia Corp | 15.97m | -107.69m | 982.28m | 136.00 | -- | 11.38 | -- | 61.57 | -1.57 | -1.57 | 0.2359 | 1.13 | 0.098 | -- | 4.77 | 117,404.40 | -66.06 | -55.02 | -72.44 | -62.69 | 76.82 | 82.18 | -674.42 | -474.59 | 7.50 | -28.61 | 0.4944 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
OPKO Health Inc | 799.60m | -252.43m | 982.76m | 3.93k | -- | 0.7622 | -- | 1.19 | -0.3427 | -0.3427 | 1.08 | 1.80 | 0.3859 | 7.53 | 6.87 | 203,461.30 | -12.18 | -7.14 | -13.58 | -8.14 | 32.63 | 34.42 | -31.56 | -13.83 | 1.58 | -4.96 | 0.2217 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
Arcutis Biotherapeutics Inc | 106.39m | -217.42m | 1.00bn | 296.00 | -- | 4.29 | -- | 9.10 | -2.91 | -2.91 | 1.30 | 1.95 | 0.248 | 0.6845 | 4.26 | 359,439.20 | -50.68 | -65.64 | -56.21 | -71.72 | 92.99 | -- | -204.36 | -1,513.03 | 9.61 | -6.52 | 0.4741 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
Pharvaris NV | 0.00 | -115.20m | 1.02bn | 82.00 | -- | 2.62 | -- | -- | -2.58 | -2.58 | 0.00 | 7.24 | 0.00 | -- | -- | 0.00 | -40.45 | -36.09 | -43.50 | -38.27 | -- | -- | -- | -- | -- | -127.47 | 0.0005 | -- | -- | -- | -32.15 | -- | -- | -- |
Silence Therapeutics plc | 33.64m | -44.51m | 1.02bn | 115.00 | -- | 6.72 | -- | 29.11 | -0.3911 | -0.3911 | 0.2856 | 1.13 | 0.1829 | -- | 5.37 | 292,521.00 | -24.20 | -43.60 | -27.21 | -54.91 | 69.72 | -- | -132.31 | -287.30 | -- | -- | 0.0022 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 1.04bn | 180.00 | -- | 3.96 | -- | 8.39 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
Enliven Therapeutics Inc | 0.00 | -79.60m | 1.06bn | 46.00 | -- | 3.32 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
Collegium Pharmaceutical Inc | 566.92m | 93.29m | 1.06bn | 197.00 | 16.10 | 4.88 | 4.52 | 1.91 | 2.06 | 2.06 | 12.06 | 6.79 | 0.4869 | 7.07 | 3.20 | 2,877,782.00 | 8.01 | 2.79 | 12.70 | 4.80 | 60.01 | 50.88 | 16.46 | 5.16 | 1.14 | 3.10 | 0.7372 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
Holder | Shares | % Held |
---|---|---|
Caligan Partners LPas of 31 Mar 2024 | 10.36m | 13.63% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.39m | 4.45% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.77m | 3.64% |
Kynam Capital Management LPas of 31 Mar 2024 | 2.25m | 2.96% |
Findell Capital Management LLCas of 31 Mar 2024 | 2.11m | 2.77% |
Farallon Capital Management LLCas of 31 Mar 2024 | 2.06m | 2.70% |
Vestal Point Capital LPas of 31 Mar 2024 | 2.00m | 2.63% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.23m | 1.61% |
Geode Capital Management LLCas of 31 Mar 2024 | 1.13m | 1.49% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 568.19k | 0.75% |